Less than 10% of individuals that would benefit from weight-loss injections like Wegovy have access to them, caution the WHO as it publishes its initial advice on the therapies.
Given in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is calling for increased and just availability to GLP-1 medication.
Based on forecasts, over two billion will be obese by 2030 if no action is taken.
"Our new guidance acknowledges that obesity is a lifelong illness that can be addressed with comprehensive and continuous care," said WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are significant hurdles to widespread availability to the treatments that can assist patients in reducing significant weight, says the organization.
Skinny Jab Shortage
Despite the present most favorable outlook, the supply of GLP-1 therapies could only cover about 100 million people – fewer than 10% of those who need them, per the health organization.
The recommendation urges countries and companies to increase access, through strategies like patent sharing.
The intellectual property rights on a key compound – the main component of a leading brand – is set to lapse in a number of nations in 2026.
How Obesity Jabs Function
The injections replicate a body's own hormone to slow digestion, reduce hunger and boost satiety so people eat less.
Individuals commonly begin shedding pounds after several weeks of commencing the once-weekly jabs.
Studies suggests users may see weight return within a year of discontinuing the drug, because their usual appetite resume.
Being above a healthy weight increases your likelihood for experiencing diseases, like type 2 diabetes, cardiovascular issues, brain attack, and some malignancies.
Excess weight concerns individuals in countries worldwide and was linked to 3.7 million deaths worldwide in 2024, as per the health agency.
